Clinical Trial Update: CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neoadjuvant and adjuvant nivolumab as immune checkpoint inhibition in squamous cell carcinoma of the oral cavity has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Oral Cavity

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: The Clatterbridge Cancer Centre NHS Foundation Trust | Conditions: Squamous Cell Carcinoma of the Oral Cavity | Phase 2 | Status: COMPLETED